Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
Meritxell Nomdedeu, Margherita Maffioli, Xavier Calvo, Alejandra Martínez-Trillos, Tycho Baumann, Marina Díaz-Beyá, Josep-Lluís Aguilar, María Rozman, Dolors Costa, Jordi Esteve, Francisco Cervantes, Dolors Colomer, Benet Nomdedeu
Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain. mnomde@clinic.ub.es
Leukemia research 2011 SepNo abstract available.
Citation
Meritxell Nomdedeu, Margherita Maffioli, Xavier Calvo, Alejandra Martínez-Trillos, Tycho Baumann, Marina Díaz-Beyá, Josep-Lluís Aguilar, María Rozman, Dolors Costa, Jordi Esteve, Francisco Cervantes, Dolors Colomer, Benet Nomdedeu. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation. Leukemia research. 2011 Sep;35(9):1276-8
Mesh Tags
Substances
PMID: 21764129
View Full Text
